Idelalisib

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Indolent Non-Hodgkin's Lymphoma

Conditions

Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma

Trial Timeline

Feb 1, 2011 → Aug 1, 2015

NCT ID

NCT01306643

About Idelalisib

Idelalisib is a phase 1/2 stage product being developed by Gilead Sciences for Indolent Non-Hodgkin's Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01306643. Target conditions include Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03568929	Pre-clinical	Completed	May 25, 2018	Oct 29, 2021	Follicular Non-Hodgkin's Lymphoma Refractory
NCT02739360	Approved	Terminated	May 4, 2016	Dec 28, 2017	Lymphoid Malignancies
NCT02928510	Pre-clinical	Terminated	Feb 1, 2016	Jun 5, 2018	Absence of Signs or Symptoms
NCT02536300	Phase 3	Terminated	Jan 14, 2016	Sep 27, 2022	Follicular Lymphoma
NCT02590588	Phase 2	Terminated	Jan 1, 2016	Mar 27, 2017	Amyloidosis
NCT02242045	Phase 1	Completed	Oct 1, 2014	Oct 17, 2017	Chronic Lymphocytic Leukemia
NCT01539291	Phase 3	Terminated	Oct 3, 2012	Jun 29, 2018	Chronic Lymphocytic Leukemia
NCT01393106	Phase 2	Completed	Sep 1, 2011	Aug 1, 2014	Hodgkin Lymphoma
NCT01282424	Phase 2	Completed	Mar 18, 2011	May 16, 2018	Follicular Lymphoma
NCT01306643	Phase 1/2	Completed	Feb 1, 2011	Aug 1, 2015	Indolent Non-Hodgkin's Lymphoma
NCT01090414	Phase 1/2	Terminated	Mar 22, 2010	Jun 18, 2018	Chronic Lymphocytic Leukemia

Competing Products

15 competing products in Indolent Non-Hodgkin's Lymphoma

See all competitors

Product	Company	Stage	Hype Score
ME-401	Kyowa Kirin	Phase 1	33
ME-401	Kyowa Kirin	Phase 2	52
Linperlisib ； Rituximab	Jiangsu Hengrui Medicine	Phase 1/2	41
GP2013	Novartis	Phase 1	33
Ibrutinib + GA 101	Roche	Phase 2	52
Obinutuzumab + Bendamustine	Roche	Phase 2	52
Placebo + Rituximab + Idelalisib	Gilead Sciences	Phase 3	76
Idelalisib + Rituximab + Bendamustine + Placebo	Gilead Sciences	Phase 3	76
Idelalisib + Rituximab + Bendamustine + Ofatumumab + Fludarabine + Everolimus + Bortezomib + Chlorambucil + Lenalidomide	Gilead Sciences	Phase 1	32
IBI376	Innovent Biologics	Phase 2	51
Copanlisib + Nivolumab + Rituximab	Bristol Myers Squibb	Phase 1	32
SAR245409	Sanofi	Phase 1	32
Copanlisib (BAY80-6946)	Bayer	Pre-clinical	20
Bendamustine at a dose of 100 mg/m2 + Bendamustine at a dose of 120 mg/m2	Lundbeck	Phase 3	74
Bezuclastinib	Cogent Biosciences	Pre-clinical	20

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved